Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. (SHE:301093)
China · Delayed Price · Currency is CNY 78.44
-3.55 (-4.33%)
At close: Aug 24, 2026
SHE:301093 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 16,734 | 8,239 | 2,956 | 4,380 | 3,421 | 7,030 | |
Market Cap Growth | 210.70% | 178.70% | -32.51% | 28.05% | -51.34% | - |
Enterprise Value | 15,637 | 7,100 | 2,277 | 4,008 | 1,852 | 7,076 |
Last Close Price | 78.44 | 39.29 | 13.99 | 18.42 | 14.35 | 28.91 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 394.60 | 136.91 | 59.63 | 37.14 | 36.49 | 32.54 |
Forward PE | 127.47 | 69.06 | 20.34 | 26.92 | - | - |
PS Ratio | 27.73 | 13.30 | 5.04 | 7.03 | 5.86 | 8.56 |
PB Ratio | 7.58 | 3.75 | 1.32 | 1.76 | 1.42 | 2.91 |
P/TBV Ratio | 7.89 | 3.91 | 1.37 | 1.81 | 1.43 | 2.94 |
P/FCF Ratio | - | - | - | - | - | 75.77 |
P/OCF Ratio | 125.45 | 71.33 | 24.48 | 19.57 | 36.05 | 32.46 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 25.91 | 11.46 | 3.88 | 6.43 | 3.17 | 8.62 |
EV/EBITDA Ratio | 153.95 | 60.92 | 25.54 | 34.51 | 18.31 | 25.23 |
EV/EBIT Ratio | - | 141.70 | 68.63 | 55.91 | 27.92 | 28.04 |
EV/FCF Ratio | - | - | - | - | - | 76.26 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.04 | 0.04 | 0.00 | - | - | 0.02 |
Debt / EBITDA Ratio | 0.82 | 0.77 | 0.01 | - | - | 0.15 |
Debt / FCF Ratio | - | - | - | - | - | 0.44 |
Net Debt / Equity Ratio | -0.50 | -0.54 | -0.58 | -0.63 | -0.69 | -0.76 |
Net Debt / EBITDA Ratio | -10.90 | -10.20 | -14.55 | -13.60 | -16.50 | -6.53 |
Net Debt / FCF Ratio | 135.36 | 69.55 | 88.57 | 21.53 | 21.19 | -19.73 |
Asset Turnover | 0.24 | 0.25 | 0.23 | 0.24 | 0.22 | 0.50 |
Inventory Turnover | 2.47 | 2.71 | 3.27 | 3.44 | 2.64 | 3.35 |
Quick Ratio | 8.38 | 8.28 | 8.99 | 10.85 | 13.32 | 10.03 |
Current Ratio | 9.41 | 9.16 | 9.83 | 11.49 | 14.31 | 10.74 |
Return on Equity (ROE) | 1.87% | 2.69% | 2.09% | 4.81% | 3.88% | 15.36% |
Return on Assets (ROA) | 0.79% | 1.24% | 0.80% | 1.69% | 1.59% | 9.69% |
Return on Invested Capital (ROIC) | 2.62% | 4.43% | 3.02% | 7.45% | 8.69% | 41.12% |
Return on Capital Employed (ROCE) | 1.40% | 2.10% | 1.40% | 2.80% | 2.70% | 10.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.25% | 0.73% | 1.68% | 2.69% | 2.74% | 3.07% |
FCF Yield | -0.05% | -0.21% | -0.50% | -1.68% | -2.30% | 1.32% |
Dividend Yield | 0.05% | 0.10% | 0.85% | 1.93% | 1.24% | 1.43% |
Payout Ratio | 24.65% | 43.52% | 156.65% | 34.71% | 101.22% | 2.07% |
Buyback Yield / Dilution | 2.57% | 1.44% | 5.91% | -0.97% | -26.35% | -5.62% |
Total Shareholder Return | 2.63% | 1.54% | 6.76% | 0.95% | -25.11% | -4.18% |